Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Basic) (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of EPS (Basic) data on record, last reported at -$0.19 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 67.8% year-over-year to -$0.19; the TTM value through Dec 2025 reached -$1.59, up 48.21%, while the annual FY2025 figure was -$1.59, 48.21% up from the prior year.
  • EPS (Basic) reached -$0.19 in Q4 2025 per TARS's latest filing, up from -$0.29 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.31 in Q2 2021 and bottomed at -$1.28 in Q3 2023.
  • Average EPS (Basic) over 5 years is -$0.62, with a median of -$0.62 recorded in 2024.
  • Peak YoY movement for EPS (Basic): surged 125.41% in 2021, then tumbled 436.0% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at -$0.72 in 2021, then soared by 36.11% to -$0.46 in 2022, then crashed by 176.09% to -$1.27 in 2023, then soared by 53.54% to -$0.59 in 2024, then soared by 67.8% to -$0.19 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.19 in Q4 2025, -$0.29 in Q3 2025, and -$0.47 in Q2 2025.